Table 5.
Shifts in LOCS III scores and IOP (Week 52; ophthalmological population)
| BGF MDI 320/18/9.6 μg (N = 132) | BFF MDI 320/9.6 μg (N = 54) | GFF MDI 18/9.6 μg (N = 125) | |
|---|---|---|---|
| Proportion of patients with increases in LOCS III P score, n (%) | |||
| n | 111 | 49 | 94 |
| Class 1 (≥0.5 unit) | 16 (14.4) | 6 (12.2) | 7 (7.4) |
| Class 2 (≥1.0 unit) | 12 (10.8) | 3 (6.1) | 5 (5.3) |
| Class 3 (≥1.5 units) | 8 (7.2) | 0 | 4 (4.3) |
| Proportion of patients with increases in LOCS III NO score, n (%) | |||
| n | 111 | 49 | 95 |
| Class 1 (≥0.5 unit) | 40 (36.0) | 16 (32.7) | 33 (34.7) |
| Class 2 (≥1.0 unit) | 19 (17.1) | 5 (10.2) | 11 (11.6) |
| Class 3 (≥1.5 units) | 6 (5.4) | 2 (4.1) | 3 (3.2) |
| Proportion of patients with increases in LOCS III NC score, n (%) | |||
| n | 111 | 49 | 95 |
| Class 1 (≥0.5 unit) | 30 (27.0) | 12 (24.5) | 32 (33.7) |
| Class 2 (≥1.0 unit) | 11 (9.9) | 4 (8.2) | 14 (14.7) |
| Class 3 (≥1.5 units) | 5 (4.5) | 1 (2.0) | 3 (3.2) |
| Proportion of patients with increases in LOCS III C score, n (%) | |||
| n | 110 | 49 | 95 |
| Class 1 (≥0.5 unit) | 25 (22.7) | 10 (20.4) | 17 (17.9) |
| Class 2 (≥1.0 unit) | 15 (13.6) | 6 (12.2) | 5 (5.3) |
| Class 3 (≥1.5 units) | 8 (7.3) | 4 (8.2) | 4 (4.2) |
| Proportion of patients with IOP ≥22 mmHg or increase in IOP of ≥7 mmHg, n (%)# | |||
| n | 114 | 50 | 103 |
| ≥22 mmHg | 2 (1.8) | 3 (6.0) | 4 (3.9) |
| ≥7 mmHg increase | 5 (4.4) | 2 (4.0) | 3 (2.9) |
BFF Budesonide/formoterol fumarate, BGF Budesonide/glycopyrrolate/formoterol fumarate, C Cortical cataract, GFF Glycopyrrolate/formoterol fumarate, IOP Intraocular pressure, LOCS III Lens opacities classification system III, MDI Metered dose inhaler, NC Nuclear color, NO Nuclear opalescence, P Posterior subcapsular cataract. #: in either eye